- Home
- ENTX vs SFWL Comparison
ENTX vs SFWL Comparison
Compare ENTX & SFWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENTX | SFWL |
|---|---|---|
| Founded | 2010 | 2001 |
| Country | Israel | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trucking Freight/Courier Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.0M | 78.4M |
| IPO Year | 2018 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ENTX | SFWL |
|---|---|---|
| Price | $1.59 | $0.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 124.4K | 91.8K |
| Earning Date | 11-14-2025 | 08-27-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.68 |
| EPS | N/A | ★ 0.14 |
| Revenue | $124,000.00 | ★ $540,461,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.70 |
| Revenue Growth | ★ 25.25 | 21.10 |
| 52 Week Low | $1.50 | $0.56 |
| 52 Week High | $3.22 | $1.29 |
Technical Indicators
Market Signals| Indicator | ENTX | SFWL |
|---|---|---|
| Relative Strength Index (RSI) | 30.65 | 52.19 |
| Support Level | $1.69 | $0.56 |
| Resistance Level | $2.22 | $1.18 |
| Average True Range (ATR) | 0.16 | 0.09 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 27.03 | 65.88 |
Price Performance
Historical ComparisonAbout ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.